| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Letters to the Editor |
Cedars-Sinai Medical Center Los Angeles, California 90048-1865
We appreciate the comments of Drs. Adams and Buchfelder in the letter above. As we wrote, the aim of our study was to study GHRP receptor expression in normal pituitary cells. Despite previous reports of GHRP action on tumorous adenoma cells (cited by Adams and Buchfelder), those studies all preceded the cloning of the GHRP receptor in 1996 (1), and therefore it would have been impossible for us to cite them, even as putative examples of tumor GHRP receptor expression. We appropriately cited earlier in vivo observations indicating GHRP responsiveness in normal man (2, 3, 4, 5, 6). These clinical observations in normal adults served as background for our studies in normal human pituitary cells. We did not cite previous in vitro tumor cell culture heterogenous responses, as our work was a physiologic study of normal human somatotroph GHRP receptor expression and response. We elected to restrict our citations to primary events.
Footnotes
Address correspondence to: Shlomo Melmed, Division of Endocrinology and Metabolism, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Suite B-131, Los Angeles, California 90048.
Received March 26, 1998.
References
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |